Merck (MRK) closed at $79.96, -1.91% from the previous session, compared to the S&P 500’s -0.01%. Shares rose 2.81% in the past month. Earnings report expected on July 29, 2025, with an estimated EPS of $2.01 and revenue of $15.71 billion. Recent analyst revisions suggest a Zacks Rank #4 (Sell).

Merck’s Forward P/E ratio is 9.21, lower than the industry average of 14.13. The PEG ratio is 0.85, below the industry’s 1.26. The Large Cap Pharmaceuticals industry has a Zacks Industry Rank of 74, in the top 30% of all industries. Monitor stock metrics on Zacks.com for trading insights.

Discover 5 stocks set to double, selected by Zacks experts for potential gains of +100% or more. These picks are poised for growth, with previous recommendations soaring +171%, +209%, and +232%. Download “Atomic Opportunity: Nuclear Energy’s Comeback” for free today for more insights on stock opportunities.

For the latest recommendations from Zacks Investment Research, download “7 Best Stocks for the Next 30 Days” for free. Get a free stock analysis report on Merck & Co., Inc. (MRK) for in-depth insights. Check the original article on Zacks Investment Research for more details on Merck’s performance in the market.

Read more at Nasdaq: Merck (MRK) Falls More Steeply Than Broader Market: What Investors Need to Know